Unjha Formulations Ltd.
BSE: UNJHAFOR · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Unjha Formulations Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Unjha Formulations Limited is a Gujarat-based pharmaceutical company specialising in the manufacturing and marketing of generic formulations. Its product portfolio includes tablets, capsules, and liquid orals across therapeutic categories such as antibiotics, analgesics, and nutritional supplements.
Business Model
The company generates revenue through the production and distribution of affordable generic pharmaceutical products for the domestic Indian market. It leverages a manufacturing facility that adheres to standard quality protocols to supply its diverse therapeutic range.
Growth Outlook
Growth is primarily driven by the expansion of its distribution network across regional Indian markets and the continued demand for affordable healthcare solutions. The company focuses on maintaining its presence in the ethical and generic segments of the healthcare market.
Key Risks
- Regulatory Compliance. The company faces risks associated with evolving pharmaceutical quality standards and potential changes in government drug pricing policies.
- Market Competition. Intense competition within the Indian generic pharmaceutical sector may exert pressure on profit margins and market share.
- Supply Chain Volatility. Fluctuations in the cost of active pharmaceutical ingredients and raw materials could impact production costs and overall profitability.
Start your research today
Unlock AI insights, financials, peers and live data on Unjha Formulations Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹16 Cr
TTM · standalone
NET PROFIT
₹2 Cr
TTM · standalone
EPS
₹4.92
TTM · standalone
RETURN ON EQUITY
66.1%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
53.2%
TTM · standalone
P/E
5.5x
Q4 FY26 · standalone
EV/EBITDA
3.5x
Q4 FY26 · standalone
EBITDA MARGIN
13.3%
TTM · standalone
NET PROFIT MARGIN
22.6%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Unjha Formulations Ltd.UNJHAFOR | ₹12 Cr | 5.31 | 4.84 | 12.5% | 13.3% | 66.1% | 53.2% | +5.5% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
Unjha Formulations Ltd.
BSE: UNJHAFOR · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Unjha Formulations Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Unjha Formulations Limited is a Gujarat-based pharmaceutical company specialising in the manufacturing and marketing of generic formulations. Its product portfolio includes tablets, capsules, and liquid orals across therapeutic categories such as antibiotics, analgesics, and nutritional supplements.
Business Model
The company generates revenue through the production and distribution of affordable generic pharmaceutical products for the domestic Indian market. It leverages a manufacturing facility that adheres to standard quality protocols to supply its diverse therapeutic range.
Growth Outlook
Growth is primarily driven by the expansion of its distribution network across regional Indian markets and the continued demand for affordable healthcare solutions. The company focuses on maintaining its presence in the ethical and generic segments of the healthcare market.
Key Risks
- Regulatory Compliance. The company faces risks associated with evolving pharmaceutical quality standards and potential changes in government drug pricing policies.
- Market Competition. Intense competition within the Indian generic pharmaceutical sector may exert pressure on profit margins and market share.
- Supply Chain Volatility. Fluctuations in the cost of active pharmaceutical ingredients and raw materials could impact production costs and overall profitability.
Start your research today
Unlock AI insights, financials, peers and live data on Unjha Formulations Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹16 Cr
TTM · standalone
NET PROFIT
₹2 Cr
TTM · standalone
EPS
₹4.92
TTM · standalone
RETURN ON EQUITY
66.1%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
53.2%
TTM · standalone
P/E
5.5x
Q4 FY26 · standalone
EV/EBITDA
3.5x
Q4 FY26 · standalone
EBITDA MARGIN
13.3%
TTM · standalone
NET PROFIT MARGIN
22.6%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26